These patients tended to have higher copy number alterations and/or tumor mutation burden in their metastatic disease after PIKTOR treatment, loss of DNA damage repair deficiency signatures, and increased expression of PD-1/PD-L1 pathway genes. This evidence concerns the gene CD274 and neoplasm.